Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Group 1 - Regeneron Pharmaceuticals, Inc. (REGN) share price has decreased by 22.5% over the past six months, indicating Wall Street's concerns regarding the short-term prospects of its Eylea franchise due to increased competition [1] Group 2 - The article emphasizes the importance of understanding market dynamics and competition in the pharmaceutical sector, particularly for companies like Regeneron that rely on specific product franchises [1]